We are a biotechnology company on a mission to engineer next-generation AAV capsids for the safe and precise delivery of gene therapies.
Recent years have seen significant setbacks and safety concerns in AAV gene therapy. Our platform is designed to end that cycle through first-principles engineering of the entire capsid structure—combining access to the most clinically relevant biological models, a functional transduction selection platform, and artificial intelligence.
The efficacy of the platform has been validated in-vitro and in-vivo.
A cross-disciplinary team with expertise in AAV vectorology, bioinformatics and AI.
Our AI models trained in bespoke datasets can can optimize capsids for specific therapeutic targets.
Rapid identification of lead candidates for validation and advancement to preclinical testing.